KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma

Alexandra D’Oto, Jie Fang, Hongjian Jin, Beisi Xu, Shivendra Singh, Anoushka Mullasseril, Victoria Jones, Ahmed Abu-Zaid, Xinyu Buttlar, Bailey Cooke, Dongli Hu, Jason Shohet, Andrew J. Murphy, Andrew M. Davidoff () and Jun Yang ()
Additional contact information
Alexandra D’Oto: St. Jude Children’s Research Hospital
Jie Fang: St. Jude Children’s Research Hospital
Hongjian Jin: St. Jude Children’s Research Hospital
Beisi Xu: St. Jude Children’s Research Hospital
Shivendra Singh: St. Jude Children’s Research Hospital
Anoushka Mullasseril: St. Jude Children’s Research Hospital
Victoria Jones: St. Jude Children’s Research Hospital
Ahmed Abu-Zaid: St. Jude Children’s Research Hospital
Xinyu Buttlar: St. Jude Children’s Research Hospital
Bailey Cooke: St. Jude Children’s Research Hospital
Dongli Hu: St. Jude Children’s Research Hospital
Jason Shohet: University of Massachusetts Medical School
Andrew J. Murphy: St. Jude Children’s Research Hospital
Andrew M. Davidoff: St. Jude Children’s Research Hospital
Jun Yang: St. Jude Children’s Research Hospital

Nature Communications, 2021, vol. 12, issue 1, 1-19

Abstract: Abstract The H3K27me2/me3 histone demethylase KDM6B is essential to neuroblastoma cell survival. However, the mechanism of KDM6B action remains poorly defined. We demonstrate that inhibition of KDM6B activity 1) reduces the chromatin accessibility of E2F target genes and MYCN, 2) selectively leads to an increase of H3K27me3 but a decrease of the enhancer mark H3K4me1 at the CTCF and BORIS binding sites, which may, consequently, disrupt the long-range chromatin interaction of MYCN and E2F target genes, and 3) phenocopies the transcriptome induced by the specific CDK4/6 inhibitor palbociclib. Overexpression of CDK4/6 or Rb1 knockout confers neuroblastoma cell resistance to both palbociclib and the KDM6 inhibitor GSK-J4. These data indicate that KDM6B promotes an oncogenic CDK4/6-pRB-E2F pathway in neuroblastoma cells via H3K27me3-dependent enhancer-promoter interactions, providing a rationale to target KDM6B for high-risk neuroblastoma.

Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-27502-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-27502-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-27502-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().